| PATENT REGISTER | |||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2017/044 | |||||||||||||||||||||||
| Status | Granted | Patent No. | 2464382 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 10747168.2 | Date of Filing | 12/08/2010 | ||||||||||||||||||||
| Date Grant Published | 03/05/2017 | Application Published | 20/06/2012 | ||||||||||||||||||||
| Title of Invention | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE | ||||||||||||||||||||||
| Priority |
|
||||||||||||||||||||||
| Inventors |
HERTING, Frank KLEIN, Christian |
||||||||||||||||||||||
| Current Proprietor |
Roche Glycart AG Wagistrasse 18 8952 Schlieren-Zuerich SWITZERLAND |
||||||||||||||||||||||
| Address for service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||||
| 22/06/2017 | Address for Service recorded as FRKelly, 27 Clyde Road, Ballsbridge, Dublin 4, Ireland received on 21/06/2017. | ||||||||||||||||||||||
| 31/10/2017 | Request for grant a Supplementary Protection Certificate, citing Patent number 2464382 as the relevant basic patent, in respect of the product Obinutuzumab in combination with Bendamustine filed on 26/10/2017. Reference number of request is 2017/044. | ||||||||||||||||||||||
| 08/12/2020 | Request for grant of Supplementary Protection Certification No. 2017/044 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||||||||||||||||||||||
